KIDS · OrthoPediatrics Corp.

The thesis

OrthoPediatrics, a maker of orthopedic implants and bracing for children, posted 19% revenue growth and raised its 2026 sales guidance on 27 October 2026. The shares have already run past most analysts' new targets, so the next three months turn on whether fourth-quarter sales hold up against the tough prior-year comparisons management itself flagged.

The business case is clear. Third-quarter revenue was a record $72.7 million, up 19% from $61.2 million, with both the US (+19%) and international (+18%) growing, according to the company's 27 October 2026 earnings release. Full-year guidance rose to $270.0–$273.0 million from $265.0–$269.0 million. Free cash flow turned positive at $1.6 million.

The price is the problem. The 29 October 2026 close of $31.52 sits above six of the seven price targets analysts raised on 28 October 2026. The 14-day relative strength index (RSI), a momentum gauge where readings above 70 usually mean overbought, stood at 87.4. The narrative is accelerating: seven brokers raised targets within a day of the report and an FDA clearance landed the same day, but much of that news now appears to be in the price.

Bullish and bearish views on OrthoPediatrics Corp.

The bull case on OrthoPediatrics Corp. (KIDS), in brief: Growth is broad across every segment. The bear case: The shares trade above most targets.

Bull case

• Growth is broad across every segment. Trauma & Deformity revenue rose 19% to $52.6 million and Scoliosis rose 18% to $19.2 million in the third quarter, according to the 27 October 2026 release. The clinic business (OPSB) grew more than 20%, according to management on the call.
• Guidance went up, not just reaffirmed. The 27 October 2026 raise to $270.0–$273.0 million implies 14% to 16% growth for 2026. The company's sales beat the $68.497 million consensus estimate by about $4.2 million.
• Cash burn has stopped. Third-quarter free cash flow was $1.6 million, against $3.4 million used a year earlier. Management kept its target of breakeven or better free cash flow for 2026 and adjusted EBITDA (earnings before interest, taxes, depreciation and amortisation, excluding one-off items) of about $25 million.
• New products keep arriving. On 27 October 2026 the FDA cleared the company's Pediatric Nailing Platform Femur Retrograde Nail System, and the first surgeries with it are done. Chief executive David Bailey described an "innovation super cycle" with a product pipeline over several years.
• Analysts moved up together. On 28 October 2026 Lake Street raised its target to $38, Canaccord Genuity, Piper Sandler and BTIG to $30, TD Cowen and Truist to $28, and Stifel to $27, according to Benzinga.

Bear case

• The shares trade above most targets. At $31.52 on 29 October 2026, only Lake Street's $38 target sits above the close. Truist kept a Hold rating even after lifting its target to $28 from $22.
• Management warned on the fourth quarter. On the 27 October 2026 call, management said fourth-quarter results may lack prior-year sales such as set sales to Brazil and large 7D unit sales. That makes the next quarter's growth rate harder to match.
• Profits still trail revenue. The third-quarter net loss was $5.9 million, or $0.25 per share. Adjusted earnings per share of $(0.23) missed the $(0.21) estimate, according to Benzinga, and the adjusted EBITDA margin was about 10%.
• Leverage exceeds cash. At 30 September 2026 the company held $44.9 million of cash and short-term investments, down from $62.9 million at 31 December 2025. It carried a $48.6 million term loan and a $49.0 million convertible note.
• The company has missed before. For the third quarter of 2025 it preannounced revenue of $61.2 million against a $63.63 million consensus, according to TheFly.

Price setup

The 29 October 2026 close of $31.52 is also the 52-week high, on split- and dividend-adjusted daily closes. The shares are up 51.0% over three months. That gain came mostly through steady growth reports and peaked in the session after the 27 October 2026 report.

The 14-day RSI of 87.4 is an extreme reading for a small-cap medical-device stock. The crowding visible here comes from momentum and price, not from insider selling or share issuance. No such filings appeared around the report. The nearest reference level is the analyst target range: $27 (Stifel) to $30 (Canaccord, Piper Sandler, BTIG), all below the last close.

A close back below $27 would put the shares under every raised target but Lake Street's and would mean the post-report re-rating has failed.

Catalysts, next 30 days

• ~early March 2027, est.: fourth-quarter 2026 report and first 2027 guidance.

No company-confirmed catalyst falls in the next 30 days.

Elapsed catalysts

• ~mid-November 2026, est.: possible investor-conference appearances. The company presented at the Jefferies healthcare conference on 18 November 2025, but no 2026 date has been announced. Any update on fourth-quarter demand or 2027 targets would matter. (passed 347d ago)
• ~mid-January 2027, est.: preliminary fourth-quarter and full-year 2026 revenue (outside the 30-day window). This is the first hard read on whether sales clear the $270.0 million guidance floor despite the prior-year comparisons flagged on 27 October 2026. (passed 4d ago)

What would change the view

The case breaks if fourth-quarter revenue brings full-year 2026 sales in below the $270.0 million guidance floor. It also breaks if free cash flow for 2026 ends negative after management repeated its breakeven target on 27 October 2026. A further fall in cash from the $44.9 million reported at 30 September 2026, or new debt or equity financing, would weaken the balance-sheet side of the argument.

On price, a daily close below $27 would mean the market has rejected the post-report re-rating. That level is Stifel's target, the lowest of the seven raised on 28 October 2026.

The read would turn more constructive if 2027 guidance pointed to growth near the 2026 rate of 14% to 16% with rising adjusted EBITDA margins. More brokers moving targets above $31.52 would point the same way.

What it trades with

OrthoPediatrics sits in the medtech and diagnostics group alongside Glaukos (GKOS), Dexcom (DXCM), Myriad Genetics (MYGN), QuidelOrtho (QDEL), Inogen (INGN), AVITA Medical (RCEL) and Natera (NTRA). Interest in that group rose through early October 2026 and has cooled since mid-October. A cooling group sets a higher bar for a single-name story that has already run 51.0% in three months.

The business drivers are specific to the company: pediatric surgery volumes, how many implant sets it places with hospitals, and launches such as the 27 October 2026 nail-system clearance. Day to day, the shares are likely to trade more with small-cap growth stocks and interest-rate expectations than with large-cap device makers. The company's $98 million of term-loan and convertible debt adds sensitivity to credit conditions.